HotPennyStockNews.com is devoted to fetch you the most exclusive stocks in the market today. Apart from scanning the markets for the most underrated stocks. We propel those victors directly to your email inbox first ahead of the rest of the marketplace gets a prospect.
Los Angelas, CA -- (SBWIRE) -- 01/11/2013 -- Infosys Ltd ADR (NYSE:INFY) augmented 15.13% to $50.60 in the pre-market trading hours. The company increased the revenue and earnings guidance for 2013. The Company expects revenues to be at least $7.450 billion and earning per American Depositary Share is expected to be at least $2.97 for 2013. However, analysts on an average are expecting the Company to report revenues of $7.319 billion for fiscal 2013.
How To Trade INFY Now After The Recent Volatile Moves? Find Out Here
Best Buy Co., Inc. (NYSE:BBY) is rising 5 percent to $12.85. The company's revenues for the nine-week holiday season ended January 5 fell 0.4 percent from the year-ago period, with comparable store sales declining 1.4 percent. The company's domestic revenues declined 1.2 percent, while international revenues grew 2.2 percent. Meanwhile, the company lowered its fiscal 2013 free cash flow guidance.
How Should Investors Trade BBY Now? Find Out Here
KBR Inc. (NYSE:KBR) is down 9 percent to $29.00 as it slashed its fiscal year 2012 adjusted earnings per share outlook due to significant project charges it expects to take in both its miners and U.S. construction businesses in the fourth quarter as well as higher than expected labor cost absorption expenses. The company noted that it is clearly disappointed with its outlook for the 2012 fourth quarter.
How To Trade KBR After The Recent Momentum? Find Out Here
ArQule Inc (NASDAQ:ARQL) plunged 19.18% in the pre-market trading hours to $2.36. The stock is down after the announcement of results of a randomized Phase 2 signal generation trial of tivantinib used in combination with irinotecan and cetuximab in patients with refractory or relapsed colorectal cancer. The trial did not meet primary endpoint of Progression-Free Survival, analysis of patients enrolled showed that median PFS was 8.3 months in the experimental arm compared with 7.3 months in control arm.
How Should Investors Trade ARQL After Today’s Fall? Find Out Here
Neither HotPennyStockNews.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor or broker dealer in any jurisdiction whatsoever and none of the information provided by HotPennyStockNews.com, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation. HotPennyStockNews.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through HotPennyStockNews.com. Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to lose your entire investment. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein..
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-321-1250 (International)